AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-20. (Cancelled)

21. (withdrawn-currently amended) A compound corresponding to the following general formula:



(I)

in which:

- m represents an integer equal to 5, 6 or 7;
- n and n' represent an integer from 1 to 5, n and n' being able to be identical or different;
- the A groups, identical or different, represent a hydrogen atom, an acyl, alkyl, hydroxyalkyl or sulphoalkyl group of 1 to 16 carbon atoms,
- X represents O or S,
- Y represents:

* an $-NR_1-$ group, R_1 representing a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms, or

* an amide group of formula $-NH-CO-(CH_2)_q-NR_1-$, q representing an integer from 1 to 5 and R_1 being as defined above, or

* a cysteaminyl group of formula $-S-(CH_2)_r-NR_1-$, r representing an integer from 2 to 5 and R_1 being as defined above,

- W represents CH or N;

- Z represents:

~~* a hydrogen atom or~~

* a carbamate substituent of formula  or

* an amine substituent of formula  or

* a quaternary ammonium group of formula  or

* a urea or thiourea substituent of formula  or

* a group of formula  or

* a group of the form $C(=O)OR_3$, a group of the form $C(=O)R_2$ or a group carrying the amine, ammonium quaternary urea or thiourea functionalities, of respective formulae



p representing an integer from 0 to 5, when W represents CH, and from 2 to 5, when W represents N,

X' representing O or S,

R_2 representing a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms, ~~and being in particular a methyl, ethyl, propyl or butyl group,~~

R_3 representing a substituent allowing the hydrolysis of the carbamate group in order to release the amine function, ~~such as the tert-butyl, 9-fluorenylmethyl, benzyl, allyl or 2,2,2-trichloroethyl groups~~, and

R representing a hydrogen atom, a linear or branched alkyl group of 1 to 12 carbon atoms, or an aromatic group ~~such as the phenyl, benzyl or naphthyl group~~, or ~~derivatives of these~~ aromatic groups carrying substituents on the aromatic ring ~~such as the methyl, ethyl, chlorine, bromine, iodine, nitro, hydroxyl, methoxyl or acetamido substituents~~, or

R representing a biological recognition element ~~such as an amino acid derivative, a peptide, a monosaccharide, an~~

~~oligosaccharide~~, a multiplication element with several branchings, which branchings comprise glucide groups which can be identical or different, or also a fluorescent or radioactive visualization or detection probe.

22. (withdrawn) The compound of claim 21, characterized in that n and n' are equal.

23. (withdrawn) The compound of claim 21, characterized in that all the A groups represent a hydrogen atom.

24. (withdrawn) The compound of claim 21, characterized in that all the A groups represent a hydrogen atom, and in that Y represents either an NR_1 group, or an $-NH-CO-(CH_2)_q-NR_1-$ group, or an $-S-(CH_2)_r-NR_1-$ group, and corresponding to one of the following formulae respectively:



(I-a)



(I-b)



(I-c)

in which n, m, q, r, X, W, Z and R_1 are as previously defined.

25. (withdrawn) The compound of claim 21, characterized in that all the A groups represent a hydrogen atom, and in that Z represents either a $-(CH_2)_p-NHR_2$ group, or

a $-(CH_2)_p-N(R_2)_3$ group, or a group of formula  , in which X' represents a sulphur atom, and corresponding to one of the following formulae respectively:



(I-d)



(I-e)



(I-f)

in which n, m, p, X, W, Y, R and R_2 are as previously defined.

26. (withdrawn) The compound of claim 21, characterized in that all the A groups represent a hydrogen atom, in that W represents a nitrogen atom and in that Z represents either a group of formula $-CO-(CH_2)_p-NHR_2$, or a group of formula $-CO-(CH_2)_p-N(R_2)_3$, or a

group of formula 

in which X' represents a sulphur atom, or a

group of formula 

in which X' represents a sulphur atom and

corresponding to one of the following formulae respectively:



(I-g)



(I-h)



(I-i)



(I-j)

in which n, m, p, X, Y, R and R_2 are as previously defined.

27. (withdrawn-currently amended) The compound of claim 21, characterized in that R is chosen from the following groups:

- an alkyl group of 1 to 12 carbon atoms, linear or branched~~, and preferably being the methyl group~~;
- an aromatic group ~~such as phenyl, benzyl, naphthyl~~ or ~~derivatives of these~~ aromatic groups carrying substituents on the aromatic ring~~, and preferably being the phenyl group~~;
- the α-D-mannopyranosyl group, of the following formula (III):



(III)

- the β-lactosyl group, of the following formula (III-a):



(III-a)

- the group derived from Lewis X trisaccharide or from sialyl Lewis X tetrasaccharide, of the following formulae (III-b) and (III-c) respectively:



(III-b)



(III-c)

- an oligosaccharide derived from heparin, of the following formula (III-d):



(III-d)

28. (withdrawn) The compound of claim 21, characterized in that R comprises a branching element derived from tris(2-hydroxymethyl)methylamine, and represents one of the following groups:

- the tris(α-D-mannopyranosyloxymethyl)methyl group, of the following formula (IV):



(IV)

- the tris(β-lactosyloxymethyl)methyl group, of the following formula (IV-a):



(IV-a)

29. (withdrawn-currently amended) The compound of claim 21, characterized in that R comprises a branching element derived from pentaerythritol, said compound corresponding to one of the following formulae:



(II-a)



(II-b)



(II-c)

in which m, n, p, X, X', Y are as previously defined,

and

R_3 and R_4 represent ~~glucide derivatives~~ glucosides which can be different or identical or also a fluorescent or radioactive probe.

30. (withdrawn) The compound of claim 21, characterized in that R comprises a branching element derived from pentaerythritol, said compound corresponding to one of the following formulae:



(II-a)



(II-b)



(II-c)

in which m, n, p, X, X', Y are as previously defined,

and

R_3 and R_4 represent one of the following groups:

- the α-D-mannopyranosyl group, of formula (III):



(III)

- or the β-lactosyl group, of formula (III-a):



(III-a)

- or the β-D-glucopyranosyl group, of the following formula (VI):



(VI)

R^3 and R^4 being able to be identical or different.

31. (withdrawn) The compound of claim 21, characterized in that R comprises a branching element derived from tris(2-aminoethyl)amine (TREN), said compound corresponding to one of the following formulae:



(V-a)



(V-b)



(V-c)

m, n, p, X, X', Y being as previously defined, and R' having the definition given previously for R.

32. (withdrawn) The compound of claim 21, characterized in that R comprises a branching element derived from tris(2-aminoethyl)amine (TREN), said compound corresponding to one of the following formulae:



(V-a)



(V-b)



(V-c)

m, n, p, X, X', Y being as previously defined, and

wherein R' represents

- the α-D-mannopyranosyl group, of formula (III):



(III)

- or the β-lactosyl group of formula (III-a):



(III-a)

- or the tris(α-D-mannopyranosyloxymethyl)methyl group, of formula (IV):



(IV)

- or the tris(β-lactyloxymethyl)methyl group, of formula (IV-a).



(IV-a)

33. (withdrawn) The compound of claim 21, characterized in that m is equal to 6.

34. (withdrawn-currently amended) A method for preparing a compound according to claim 21, characterized in that it comprises the following stages:

- the reaction of a compound selectively functionalized in primary alcohol position with an amine group, of the following formula (VII):



(VII)

m, A and Y being as defined previously, ~~and A preferably being a hydrogen atom~~,

with a dimerization element of diisocyanate or diisothiocyanate type~~, in particular carrying a protected amine functionality in the form of a carbamate group or carrying a positively charged quaternary ammonium salt functionality,~~ of the following formula (VIII):



(VIII)

* n and n' being as defined previously,

~~and preferably being equal,~~

* W and X being as previously defined,

* Z' representing a group corresponding to one of the following formulae:





p, R_2 and R_3 being as defined previously,

in order to obtain a compound, corresponding to the following formula (IX):



(IX)

- and optionally the hydrolysis reaction of the



group as defined above, present in the compounds of the abovementioned formula (IX), in which Z′ contains such a group, in order to obtain a compound carrying a free amine functionality and corresponding to the following formula (X):



(X)

* n, n,′ A, X, Y, W and m being as defined previously, and

* Z′′ corresponding to the hydrolysate of the Z′ group containing a $-COOR_3$ function, and representing a hydrogen atom or corresponding to one of the following formulae:



p and R_2 being as defined previously,

- and optionally the reaction of a compound of formula (X) as obtained in the preceding stage, with an isocyanate or an isothiocyanate of the following formula (XI):

$$R—N=C=X'$$

R and X' being as defined previously,

in order to obtain a compound corresponding to the following formula (XII):



(XII)

* n, n,' A, X, Y, W and m being as defined previously, and

* Z''' corresponding to one of the following formulae:



p, R_2, X' and R being as previously defined.

35. (previously presented) An inclusion complex of a compound according to claim 21, with a pharmacologically active

molecule, the molar ratio between the compound and the pharmacologically active molecule being approximately 10:1 to approximately 1:2.

36. (currently amended) An inclusion complex of a compound according to claim 21, with a pharmacologically active molecule, the molar ratio between the compound and the pharmacologically active molecule being approximately 10:1 to approximately 1:2, characterized in that the pharmacologically active molecule is a ditopic molecule, capable of interacting simultaneously with two cyclodextrin sub-units, ~~such as a molecule having two aromatic rings, such as for example a Taxol derivative,~~ or a sufficiently large size~~, such as for example a steroid~~.

37. (currently amended) An inclusion complex of a compound according to claim 21, with a pharmacologically active molecule, the molar ratio between the compound ~~1and~~ and the pharmacologically active molecule being approximately 10:1 to approximately 1:2, characterized in that the pharmacologically active molecule is an antineoplastic agent~~, belonging in particular to the taxol family~~.

38. (withdrawn) A pharmaceutical composition comprising a compound according to claim 21, with a pharmacologically acceptable vehicle.

39. (previously presented) A pharmaceutical composition comprising an inclusion complex of a compound according to claim 21, with a pharmacologically active molecule, the molar ratio between the compound and the pharmacologically active molecule being approximately 10:1 to approximately 1:2, in association with a pharmacologically acceptable vehicle.

40. (withdrawn) A pharmaceutical composition comprising a compound according to claim 21, with a pharmacologically acceptable vehicle, in the form of aqueous solution.

41. (currently amended) A pharmaceutical composition comprising an inclusion complex of a compound according to claim 21, with a pharmacologically active molecule, the molar ratio between the compound and the pharmacologically active molecule being approximately 10:1 to approximately 1:2, in association with a pharmacologically acceptable vehicle, in the form of aqueous solution.

42. (withdrawn) A pharmaceutical composition comprising a compound according to claim 21, with a pharmacologically acceptable vehicle, characterized in that it contains per unit dose approximately 50 mg to approximately 500 mg of one of the compounds.

43. (previously presented) A pharmaceutical composition comprising an inclusion complex of a compound according to claim 21, with a pharmacologically active molecule, the molar ratio between the compound and the pharmacologically active molecule being approximately 10:1 to approximately 1:2, in association with a pharmacologically acceptable vehicle, characterized in that it contains per unit dose approximately 100 mg to approximately 750 mg of one of said complex.